15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 6 firms covering CAMP4 THERAPEUTICS CORPORATION, 6 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $6.50 to $12.00, a moderate spread. The average target of $8.42 sits 145% above the current $3.44. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 5 to 6 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.19 next quarter toward $-0.78 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 ratings
Moderate Buy
Strong Buy00%
Buy6100%
Hold00%
Sell00%
Strong Sell00%
Based on 6 analysts giving stock ratings to CAMP4 THERAPEUTICS CORPORATION.
As of Jul, 6 of 6 firms rate CAMP a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
CAMP EPS & revenue forecast
EPS · NEXT QUARTER
$-0.19
Range $-0.24 – $-0.14 · 4 analysts · -65% YoY
Next period, 4 analysts expect CAMP4 THERAPEUTICS CORPORATION to earn $-0.19 a share (range $-0.24 – $-0.14), versus $-0.54 a year earlier. Full-year consensus is $-0.79, growing to $-0.78 the year after.
REVENUE · NEXT QUARTER
$1.9M
Range $750.0K – $2.8M · 4 analysts · +138% YoY
Revenue is expected to reach $1.9M (range $750.0K – $2.8M), +137.7% year-over-year. Full-year consensus is $6.3M, rising to $6.8M next year.
Top analysts covering CAMP4 THERAPEUTICS CORPORATION
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CAMP.
#1
Anupam Rama
JP Morgan · Rank #62
Buy
$9.00+161.6% to target
Overall win rate
46%
+ Follow
#2
Keay Nakae
Chardan Capital · Rank #130
Buy
$6.50+89.0% to target
Overall win rate
41%
+ Follow
#3
Edward Tenthoff
Piper Sandler · Rank #277
Buy
$12.00+248.8% to target
Overall win rate
29%
+ Follow
#4
Mani Foroohar
Leerink Partners
Buy
$9.00+161.6% to target
Coverage
—
+ Follow
#5
YZ
Yun Zhong
Wedbush
Buy
$8.00+132.6% to target
Coverage
—
+ Follow
CAMP stock forecast FAQ
What is CAMP's average 12-month price target?+
The 6 analysts with a live target average $8.42 for CAMP4 THERAPEUTICS CORPORATION over the next 12 months, ranging from a $12.00 high to a $6.50 low.
Is CAMP stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 6 analyst ratings, 6 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for CAMP?+
The Street-high target is $12.00 (Piper Sandler), and the Street-low is $6.50 (Chardan Capital). The average of all 6 active targets is $8.42.
How many Wall Street analysts cover CAMP?+
6 analysts have an active rating on CAMP4 THERAPEUTICS CORPORATION, and 6 firms carry a live 12-month price target.
Who is the most accurate analyst covering CAMP?+
Among analysts who currently cover CAMP, Anupam Rama of JP Morgan has the strongest overall Quantellect track record (Rank #62). Their current call is Buy with a $9.00 target.
What is CAMP4 THERAPEUTICS CORPORATION's projected EPS for next quarter?+
The consensus estimate is $-0.19 per share (range $-0.24 – $-0.14) across 4 analysts. Full-year EPS is projected at $-0.79, rising to $-0.78 the following year.
How much revenue is CAMP4 THERAPEUTICS CORPORATION expected to report next quarter?+
Consensus revenue is $1.9M (range $750.0K – $2.8M). Full-year revenue is projected at $6.3M, growing to $6.8M next year.
Have analysts been upgrading or downgrading CAMP lately?+
As of Jul, 6 of 6 firms rate CAMP a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CAMP calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
